Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing emergent cardiac surgery during dual antiplatelet therapy.
Condition or disease
Blood for measuring platelet function is drawn before induction of anesthesia
Calculated blood loss [ Time Frame: until postoperative day 5 ]
Secondary Outcome Measures
BARC bleeding [ Time Frame: until postoperative day 2 ]
Intracranial bleed within 48 hours, Reoperation after closure of sternotomy for the purpose of controlling bleeding, Transfusion of equal to or more than 5 Units of packed red blood cells within a 48-hour period, Chest tube output of equal to or more than 2 L within a 24-h period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients needing emergent cardiac surgery under dual antiplatelet therapy
First time on-pump CABG with or without valve replacement